Sorrento Therapeutics (SRNE) Competitors $0.0021 0.00 (-16.00%) As of 06/12/2025 03:12 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsInsider TradesSEC FilingsShort InterestSustainabilityTrendsBuy This Stock SRNE vs. ALZN, WINT, GRI, JAGX, SPRB, PBM, SCNI, PTN, AWH, and TNFAShould you be buying Sorrento Therapeutics stock or one of its competitors? The main competitors of Sorrento Therapeutics include Alzamend Neuro (ALZN), Windtree Therapeutics (WINT), GRI Bio (GRI), Jaguar Health (JAGX), Spruce Biosciences (SPRB), Psyence Biomedical (PBM), Scinai Immunotherapeutics (SCNI), Palatin Technologies (PTN), Aspira Women's Health (AWH), and TNF Pharmaceuticals (TNFA). These companies are all part of the "pharmaceutical products" industry. Sorrento Therapeutics vs. Its Competitors Alzamend Neuro Windtree Therapeutics GRI Bio Jaguar Health Spruce Biosciences Psyence Biomedical Scinai Immunotherapeutics Palatin Technologies Aspira Women's Health TNF Pharmaceuticals Sorrento Therapeutics (NASDAQ:SRNE) and Alzamend Neuro (NASDAQ:ALZN) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, media sentiment, dividends, valuation, profitability, community ranking, institutional ownership, earnings and analyst recommendations. Do institutionals & insiders have more ownership in SRNE or ALZN? 0.0% of Sorrento Therapeutics shares are owned by institutional investors. Comparatively, 49.6% of Alzamend Neuro shares are owned by institutional investors. 2.6% of Sorrento Therapeutics shares are owned by insiders. Comparatively, 30.2% of Alzamend Neuro shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Do analysts recommend SRNE or ALZN? Alzamend Neuro has a consensus price target of $180.00, indicating a potential upside of 5,542.63%. Given Alzamend Neuro's stronger consensus rating and higher possible upside, analysts clearly believe Alzamend Neuro is more favorable than Sorrento Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sorrento Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Alzamend Neuro 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media refer more to SRNE or ALZN? In the previous week, Alzamend Neuro had 3 more articles in the media than Sorrento Therapeutics. MarketBeat recorded 3 mentions for Alzamend Neuro and 0 mentions for Sorrento Therapeutics. Alzamend Neuro's average media sentiment score of 0.62 beat Sorrento Therapeutics' score of 0.00 indicating that Alzamend Neuro is being referred to more favorably in the news media. Company Overall Sentiment Sorrento Therapeutics Neutral Alzamend Neuro Positive Is SRNE or ALZN more profitable? Company Net Margins Return on Equity Return on Assets Sorrento TherapeuticsN/A N/A N/A Alzamend Neuro N/A N/A -289.14% Which has better valuation & earnings, SRNE or ALZN? Alzamend Neuro has lower revenue, but higher earnings than Sorrento Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSorrento Therapeutics$60.32M0.02-$572.84MN/AN/AAlzamend NeuroN/AN/A-$9.95MN/AN/A Does the MarketBeat Community prefer SRNE or ALZN? Sorrento Therapeutics received 603 more outperform votes than Alzamend Neuro when rated by MarketBeat users. However, 87.50% of users gave Alzamend Neuro an outperform vote while only 67.33% of users gave Sorrento Therapeutics an outperform vote. CompanyUnderperformOutperformSorrento TherapeuticsOutperform Votes61067.33% Underperform Votes29632.67% Alzamend NeuroOutperform Votes787.50% Underperform Votes112.50% Which has more volatility and risk, SRNE or ALZN? Sorrento Therapeutics has a beta of 0.97, meaning that its share price is 3% less volatile than the S&P 500. Comparatively, Alzamend Neuro has a beta of -0.28, meaning that its share price is 128% less volatile than the S&P 500. SummaryAlzamend Neuro beats Sorrento Therapeutics on 9 of the 13 factors compared between the two stocks. Get Sorrento Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SRNE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SRNE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SRNE vs. The Competition Export to ExcelMetricSorrento TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.16M$3.12B$5.61B$8.62BDividend YieldN/A1.56%5.28%4.17%P/E RatioN/A32.9027.2119.96Price / Sales0.02466.20408.49157.63Price / CashN/A168.6838.2534.64Price / BookN/A3.427.074.69Net Income-$572.84M-$72.35M$3.23B$248.14M7 Day PerformanceN/A2.59%0.68%0.91%1 Month PerformanceN/A20.47%9.59%5.71%1 Year PerformanceN/A-17.11%32.02%14.71% Sorrento Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SRNESorrento Therapeutics0.3572 of 5 stars$0.00-16.0%N/A-83.8%$1.16M$60.32M0.00800Gap DownALZNAlzamend Neuro2.934 of 5 stars$3.50-8.6%$180.00+5,042.9%-92.8%$2.80MN/A0.004Short Interest ↑WINTWindtree Therapeutics1.7192 of 5 stars$0.75-1.5%$350.00+46,579.1%-99.6%$2.75MN/A-0.0530Short Interest ↑Gap DownGRIGRI Bio2.0812 of 5 stars$1.28-5.2%$22.00+1,618.8%-97.5%$2.74MN/A-0.111Analyst ForecastShort Interest ↑Analyst RevisionJAGXJaguar Health2.5931 of 5 stars$4.06-7.7%$60.00+1,377.8%-95.8%$2.74M$11.55M0.0050SPRBSpruce Biosciences2.131 of 5 stars$0.06-2.4%$2.17+3,296.0%-88.3%$2.69M$4.91M-0.0720News CoverageShort Interest ↑PBMPsyence BiomedicalN/A$4.64-5.5%N/A-98.8%$2.65MN/A0.00N/AGap DownSCNIScinai Immunotherapeutics0.6621 of 5 stars$2.50-8.1%N/A-13.4%$2.50M$658K-0.0120News CoverageShort Interest ↑PTNPalatin TechnologiesN/A$0.09-44.6%N/AN/A$2.45M$350K-0.0630Gap DownHigh Trading VolumeAWHAspira Women's Health0.993 of 5 stars$0.08-12.5%$5.50+6,607.3%-95.6%$2.44M$9.18M-0.07110High Trading VolumeTNFATNF PharmaceuticalsN/A$0.17+6.6%N/AN/A$2.43MN/A-0.036Gap DownHigh Trading Volume Related Companies and Tools Related Companies Alzamend Neuro Competitors Windtree Therapeutics Competitors GRI Bio Competitors Jaguar Health Competitors Spruce Biosciences Competitors Psyence Biomedical Competitors Scinai Immunotherapeutics Competitors Palatin Technologies Competitors Aspira Women's Health Competitors TNF Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SRNE) was last updated on 6/13/2025 by MarketBeat.com Staff From Our PartnersUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredWhy July 22nd Could Mean Big Changes for Social SecurityIn a stunning move, President Trump has authorized an AI-led transformation of federal agencies, including Soc...Altimetry | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredNew Rule Hits in July — The Smart Money Already MovedA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sorrento Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sorrento Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy SRNE Stock Free SRNE Stock Alerts